New biosimilar aims to match phesgo for HER2+ breast cancer
NCT ID NCT07601620
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study tests a new biosimilar drug (HLX319) to see if it works like the approved drug Phesgo for people with HER2-positive early or locally advanced breast cancer. About 258 participants will receive either HLX319 or Phesgo before surgery to compare how the drug moves through the body, its effectiveness, and safety. The goal is to offer a more affordable treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.